A national cohort study in Denmark, published in 2009, found that the risk of VTE was directly related to duration of use and the dosage of estrogen.H More significantly, those investigators found that specific progestin types, including drospirenone
, desogestrel, and gestodene, were also associated with increased VTE risk.
In 2001, Yasmin (0.03 mg of ethinyl estradiol with 3 mg of drospirenone
) was the first COC that contained drospirenone
, a spironolactone analogue, that was approved, followed by Yaz (0.02 mg of ethinyl estradiol with 3 mg of drospirenone
) in 2006.
A new monophasic oral contraceptive containing drospirenone
. Effect on premenstrual symptoms.
The COCs that contain drospirenone
as the progestin component are Yasmin (0.03 mg of ethinyl estradiol with 3 mg of drospirenone
), approved in 2001, the first COC that contained drospirenone
; Yaz (0.02 mg of ethinyl estradiol with 3 mg of drospirenone
), approved in 2006; and Safyral and Beyaz, folate-containing versions of Yasmin and Yaz, respectively, which were approved in 2010.
After adjustment for age, calendar year, education, and length of OC use, the relative risk of VTE in women who used pills with desogestrel, drospirenone
, or gestodene was found to be twice that of women on levo-norgestrel-containing pills.
US-based Jubilant Cadista Pharmaceuticals is recalling a number of Drospirenone
and Ethinyl Estradiol Tablets, USP, 3mg/ 0.02mg, 28x3 Blister Pack/Carton that had been on sale to consumers, it was reported yesterday.
M2 PHARMA-July 25, 2019-Jubilant Cadista Pharmaceuticals recalls batch of Drospirenone
and Ethinyl Estradiol Tablets
Contract award notice: Conclusion of non-exclusive discount agreements pursuant to section 130a (8) sgb v on medicines containing the active substance drospirenone
and ethinylestradiol (atc: G03aa12) within the framework of a so-called open-house model.
Women's health company Exeltis USA Inc reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for its new drug application (NDA) for the novel oestrogen-free oral contraceptive Slynd with drospirenone
in 4 mg.
, a spironolactone derivative without androgenic effect and with antimineralocorticoid effect, is the progestin component in fourth generation contraceptives released in 2006.
launch of drospirenone
and ethinyl estradiol tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz tablets.
In this chapter, most of them were seems prohibited, except drospirenone